Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Garst Seed Company was a pioneering American agricultural biotechnology firm that specialized in the development and commercialization of hybrid corn and genetically modified crop seeds. Founded in 1931 by Roswell Garst in Slater, Iowa, the company became a cornerstone of the hybrid seed industry and played a significant role in the global "Green Revolution." Garst was a leader in integrating advanced biotechnology traits, such as insect resistance and herbicide tolerance, into high-performing seed genetics. After several ownership transitions involving ICI, Zeneca, and Advanta, the company was acquired by Syngenta in 2004. Syngenta eventually retired the Garst brand in 2014, consolidating its products into the Golden Harvest and NK Seeds portfolios.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Garst.